Corbus Pharmaceuticals Completes Enrollment of Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
The company expects to report topline data from the study in the summer of 2020.
Read More
Category: Biomedical
![CURE Pharmaceutical [OTCQB:CURR] Takes First Step to Acquire Coeptis Pharmaceuticals and its Combination Drug for Osteoarthritis Pain and Hypertension](https://www.investinweed.com/wp-content/uploads/Cure-Pharmaceutical-627x376.png)
CURE Pharmaceutical [OTCQB:CURR] Takes First Step to Acquire Coeptis Pharmaceuticals and its Combination Drug for Osteoarthritis Pain and Hypertension
The planned acquisition has the potential to accelerate its 505(b)(2) drug pipeline and expedite its growth with a planned 2020 launch of Consensi.
Read More
Corbus Pharmaceuticals Updates Data from Lenabasum Open-Label Extension Studies in Systemic Sclerosis and Dermatomyositis at 2019 ACR Annual Meeting
Median ACR CRISS score remains 0.95 at 25 months in systemic sclerosis OLE.
Read More
Cara Therapeutics Announces Publication of Difelikefalin (KORSUVA™ Injection) KALM™-1 Phase 3 Trial Results in the New England Journal of Medicine
51.9% of patients in the difelikefalin group achieved the pre-specified primary outcome.
Read More
GW Pharmaceuticals receives positive NICE recommendation for EPIDYOLEX® (cannabidiol) oral solution for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy
Cannabidiol oral solution is recommended as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome.
Read MoreGET LISTED
